Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBT6050 +/- PD-1 inhibitors in HER2+ solid tumors
NCT04460456Phase 1Unknown
- Sponsor
- Silverback Therapeutics
- Start
- Jul 2020
- Primary completion
- Dec 2022
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 3
01
Overview
Phase 1, open-label trial of pertuzumab zuvotolimod in solid tumor (3 arms), sponsored by Silverback Therapeutics. Primary endpoints: Dose Limiting Toxicities at 28 days, Adverse Events at 2 years and 2 more. Status: unknown.
02
Drugs
pertuzumab zuvotolimod
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04460456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04460456.